$AVIR
Atea Pharmaceuticals, Inc.

2023 Q1 Form 10-K Financial Statement

#000095017023005186 Filed on February 28, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.62M $12.36M $48.71M
YoY Change 0.58% -6.29% 6.4%
% of Gross Profit
Research & Development $20.01M $14.72M $81.94M
YoY Change -32.49% -62.99% -51.0%
% of Gross Profit
Depreciation & Amortization $104.0K $104.0K $260.0K
YoY Change 1385.71% 1385.71% 796.55%
% of Gross Profit
Operating Expenses $32.62M $27.08M $130.7M
YoY Change -22.66% -48.87% -38.66%
Operating Profit -$41.57M -$130.7M
YoY Change -1.44% -194.42%
Interest Expense $6.299M $5.591M $11.15M
YoY Change 6327.55% 10862.75% 5135.21%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$35.27M -$34.31M -$119.5M
YoY Change -16.18% -128.3% -186.22%
Income Tax $197.0K $123.0K -$3.590M
% Of Pretax Income
Net Earnings -$35.47M -$34.43M -$115.9M
YoY Change -15.71% -129.4% -195.64%
Net Earnings / Revenue
Basic Earnings Per Share -$0.43 -$1.39
Diluted Earnings Per Share -$0.43 -$0.41 -$1.39
COMMON SHARES
Basic Shares Outstanding 83.34M 83.29M 83.25M
Diluted Shares Outstanding 83.33M 83.25M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $620.5M $646.7M $646.7M
YoY Change -12.06% -15.39% -15.39%
Cash & Equivalents $183.3M $188.5M $188.5M
Short-Term Investments $437.2M $458.2M $458.2M
Other Short-Term Assets $11.90M $14.21M $14.21M
YoY Change 54.83% 77.04% 77.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $632.4M $660.9M $660.9M
YoY Change -11.33% -14.43% -14.43%
LONG-TERM ASSETS
Property, Plant & Equipment $3.852M $1.705M $4.094M
YoY Change 405.51% 7313.04% 2125.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.889M $1.494M $1.692M
YoY Change 519.34% 220.6% 454.75%
Total Long-Term Assets $5.741M $5.786M $5.786M
YoY Change 45.08% 1083.23% 1083.23%
TOTAL ASSETS
Total Short-Term Assets $632.4M $660.9M $660.9M
Total Long-Term Assets $5.741M $5.786M $5.786M
Total Assets $638.1M $666.7M $666.7M
YoY Change -11.02% -13.74% -13.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $700.0K $2.551M $2.551M
YoY Change -80.86% -43.74% -43.74%
Accrued Expenses $11.48M $15.83M $15.83M
YoY Change -48.69% -68.2% -68.2%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.36M $18.48M $18.48M
YoY Change -56.79% -67.52% -67.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.588M $7.658M $7.658M
YoY Change -12.73% 29.1% 29.1%
Total Long-Term Liabilities $7.588M $7.658M $7.658M
YoY Change -12.73% 29.1% 29.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.36M $18.48M $18.48M
Total Long-Term Liabilities $7.588M $7.658M $7.658M
Total Liabilities $19.95M $26.14M $26.14M
YoY Change -46.52% -58.39% -58.39%
SHAREHOLDERS EQUITY
Retained Earnings -$59.88M
YoY Change -206.87%
Common Stock $83.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $618.2M $640.6M $640.6M
YoY Change
Total Liabilities & Shareholders Equity $638.1M $666.7M $666.7M
YoY Change -11.02% -13.74% -13.74%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$35.47M -$34.43M -$115.9M
YoY Change -15.71% -129.4% -195.64%
Depreciation, Depletion And Amortization $104.0K $104.0K $260.0K
YoY Change 1385.71% 1385.71% 796.55%
Cash From Operating Activities -$29.85M -$21.55M -$121.0M
YoY Change -49.41% -71.43% 39.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $1.943M
YoY Change -100.0% -100.0% 48475.0%
Acquisitions
YoY Change
Other Investing Activities $24.48M $33.49M -$453.5M
YoY Change
Cash From Investing Activities $24.48M $33.49M -$455.4M
YoY Change -55736.36% -837300.0% 11385150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 165.0K 0.000 370.0K
YoY Change -26.01% -100.0% -74.74%
NET CHANGE
Cash From Operating Activities -29.85M -21.55M -121.0M
Cash From Investing Activities 24.48M 33.49M -455.4M
Cash From Financing Activities 165.0K 0.000 370.0K
Net Change In Cash -5.205M 11.94M -576.0M
YoY Change -91.15% -115.86% 573.36%
FREE CASH FLOW
Cash From Operating Activities -$29.85M -$21.55M -$121.0M
Capital Expenditures $0.00 $0.00 $1.943M
Free Cash Flow -$29.85M -$21.55M -$122.9M
YoY Change -49.45% -71.43% 41.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001593899
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39661
CY2022 dei Entity Registrant Name
EntityRegistrantName
ATEA PHARMACEUTICALS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0574869
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
225 Franklin Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2100
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
CY2022 dei City Area Code
CityAreaCode
857
CY2022 dei Local Phone Number
LocalPhoneNumber
284-8891
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2022 dei Trading Symbol
TradingSymbol
AVIR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
537283731
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83341574
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
188460000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
764375000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
458249000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14213000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8028000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
660922000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
772403000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1705000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
198000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
305000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1494000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2389000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
161000
CY2022Q4 us-gaap Assets
Assets
666708000
CY2021Q4 us-gaap Assets
Assets
772892000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2551000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4534000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15206000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
52152000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
721000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56883000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2403000
CY2022Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
5255000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
197000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18478000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
5932000
CY2022Q4 us-gaap Liabilities
Liabilities
26136000
CY2021Q4 us-gaap Liabilities
Liabilities
62815000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83287639
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83287639
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83102730
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83102730
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
83000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
701052000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
653964000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-684000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59879000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
56030000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
640572000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
710077000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
666708000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
772892000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
351367000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
48633000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
81936000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
167205000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38023000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48714000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45785000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21640000
CY2022 us-gaap Operating Expenses
OperatingExpenses
130650000
CY2021 us-gaap Operating Expenses
OperatingExpenses
212990000
CY2020 us-gaap Operating Expenses
OperatingExpenses
59663000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-130650000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
138377000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-11030000
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
11151000
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
213000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
83000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-119499000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
138590000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10947000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3590000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-684000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17400000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-115909000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
121190000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10947000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116593000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
121190000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10947000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.39
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.46
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.39
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83245385
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82820037
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21592441
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83245385
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88249243
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21592441
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49571000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
657000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
317605000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
283230000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-10947000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
547801000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1465000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39621000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
121190000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
710077000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
230000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
140000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46718000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-684000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-115909000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
640572000
CY2022 us-gaap Profit Loss
ProfitLoss
-115909000
CY2021 us-gaap Profit Loss
ProfitLoss
121190000
CY2020 us-gaap Profit Loss
ProfitLoss
-10947000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
46718000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
39621000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7457000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
260000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
29000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
19000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-5465000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
5815000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6251000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
483000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7296000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1494000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
161000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1983000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10289000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-488000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-37623000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
43877000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
12437000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-301367000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
301367000

Files In Submission

Name View Source Status
avir-20221231_cal.xml Edgar Link unprocessable
0000950170-23-005186-index-headers.html Edgar Link pending
0000950170-23-005186-index.html Edgar Link pending
0000950170-23-005186.txt Edgar Link pending
0000950170-23-005186-xbrl.zip Edgar Link pending
avir-20221231.htm Edgar Link pending
avir-20221231.xsd Edgar Link pending
avir-20221231_htm.xml Edgar Link pending
avir-ex10_3.htm Edgar Link pending
avir-ex21_1.htm Edgar Link pending
avir-ex23_1.htm Edgar Link pending
avir-ex31_1.htm Edgar Link pending
avir-ex31_2.htm Edgar Link pending
avir-ex32_1.htm Edgar Link pending
avir-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img56668940_0.jpg Edgar Link pending
img56668940_1.jpg Edgar Link pending
img56668940_10.jpg Edgar Link pending
img56668940_11.jpg Edgar Link pending
img56668940_12.jpg Edgar Link pending
img56668940_13.jpg Edgar Link pending
img56668940_14.jpg Edgar Link pending
img56668940_2.jpg Edgar Link pending
img56668940_3.jpg Edgar Link pending
img56668940_4.jpg Edgar Link pending
img56668940_5.jpg Edgar Link pending
img56668940_6.jpg Edgar Link pending
img56668940_7.jpg Edgar Link pending
img56668940_8.jpg Edgar Link pending
img56668940_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
avir-20221231_pre.xml Edgar Link unprocessable
avir-20221231_lab.xml Edgar Link unprocessable
avir-20221231_def.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending